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culated. Methods: The costs including lab investigation charges, unit costs of 
treatment per bed, medication charges, food costs, transportation costs and loss of 
productivity were calculated per asthma episode. Data was analysed by Statistical 
Package for the Social Sciences (SPSS) version 18.0 using various descriptive and 
inferential statistical tests. Results: A median medical cost of acute exacerbation 
of asthma under Ministry of Health’s (MOH) perspective was USD 105.00 (RM338.47) 
per episode. Medication cost comprised the majority (52.38%) of the total medical 
costs. A median medical cost of acute exacerbation of asthma under patient’s per-
spective was USD 1.55 (RM4.99) per episode. ConClusions: Asthma exacerbation 
and length of stay in the hospital were proportional to the direct medical costs. In 
Malaysia, a substantial proportion of the direct medical cost of asthma treatment 
is heavily subsidised for the locals.
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objeCtives: Acute exacerbation of chronic obstructive pulmonary disease 
(AECOPD) appears to be the main reason of hospitalization in COPD patients. Since 
substantial economic burden of COPD have not been previously studied in Malaysia, 
this study aimed at estimating and identifying different costs and related burden 
of illness in patients receiving treatment of AECOPD in a tertiary care hospital in 
Malaysia. Methods: A prospective follow-up study was performed in Department 
of Accident and Emergency and Respiratory Medicine of the hospital. Data were 
derived on the basis of per exacerbation episode. Relationship between direct medi-
cal costs and disease severity was analyzed using various descriptive and inferential 
statistical approaches. Results: Median actual direct medical costs and out-of-
pocket costs were RM 457.68 (US$ 141.97) and RM 28.25 (US$ 8.76) per exacerbation 
respectively. Drug cost (41%) was the leading cost driver, followed by unit cost of 
treatment per bed (33.6%) and lab investigation cost (25.4%). However, food cost 
(44.2%) represented the largest proportion in out-of-pocket costs. More than 90% of 
actual direct medical costs were supported by the Government of Malaysia in the 
patients studied. ConClusions: Impacts of AECOPD in health care resources are 
worthy of attention. Cost information from pharmacoeconomic studies is impor-
tant in decision making for health care professionals and policy makers in order to 
improve health care outcome and minimize costs.
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objeCtives: To conduct a study to determine the average cost of therapy for bron-
chial asthma patients in a tertiary care center. Methods: A prospective obser-
vational study was carried out on a 100 bronchial asthma patients after ethical 
clearance was obtained from an Independent Ethical Review (IEC) board. The patients 
selected for the study were in-patients admitted to the Medicine and Pulmonary 
wards for bronchial asthma related complaints with and without co-morbidities. 
The study assessed the average cost of therapy which was obtained from patient 
records. Statistical analysis was performed using SPSS version 20. Results: The 
mean age of the study population (N= 100) was 53.30±14.59. Females constituted 61% 
of the study population. The job profiles of the majority of study population were 
house wives (53%) and agriculturist (15%). The average cost of therapy among 100 
patients was found to range from $1.81 to $598. The impact on the length of stay on 
cost of therapy per day was classified into ≤ 5, 6-10, 11-21 days and cost was found to 
be $9.21 ± 5.57, $12.12 ±9.65 and $15.56±10.36 respectively. Impact of co-morbidities 
(35%) and without co-morbidities on cost of therapy per day was found to be $13.03 
± 10.63 and $8.54 ± 6.77 respectively. ConClusions: Asthma creates a substantial 
financial burden on the society and results in compromise on diagnosis and treat-
ment mainly in a developing country like India. There was a substantial increase in 
the cost of therapy as the duration of hospital stay increased and also in the case 
of patients with co-morbidities. Pharmacoeconomic analysis is needed to develop 
strategies to reduce the cost of therapy and thereby achieve greater medication 
adherence and improved quality of life in asthma patients.
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objeCtives: The objective of this cost study was to measure the resource utili-
sation and the direct costs associated with health care management of patients 
with chronic obstructive pulmonary disease (COPD) in Slovakia and to provide a 
basis for cost-effectiveness evaluations. Methods: The cross-sectional survey was 
performed to obtain the information on the management of patients with COPD 
and to estimate the direct costs of the disease management. The survey included 
4 experts experienced in COPD treatment. The studied population were cohorts of 
COPD patients evaluated separately according to the stage of the disease (mild, mod-
erate, severe and very severe). The patients were treated with standard therapy, the 
cost were set for one average patient per 3 months of treatment. The cost data were 
assessed and actualized due the 1st July 2014. All types of health care used in COPD 
management were evaluated (hospitalization, outpatient visits, diagnostics, labo-
ratory tests and the management of symptoms, use of bronchodilators). Moderate 
structure of direct costs in Russia was as follows – 77% for hospital stays, 21% for out-
patient visits, 2% for ambulance service. COPD exacerbations contributed the major 
portion of cost and also correlated with disease severity. ConClusions: COPD 
associated with significant economic burden on Russian’s health care system. There 
is a striking direct relationship between the cost of care and severity of the disease 
with hospitalization leading to disease exacerbation being a major portion of cost.
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objeCtives: Atopic dermatitis is a global public health concern considering its 
growing prevalence and mounting socioeconomic burden. However, Few studies 
has assessed the economic impact of atopic dermatitis in Korea. To conduct a cost 
analysis of atopic dermatitis and evaluate the economic impact of the disease on 
individual annual disease burden, quality of life, and change in medical expenses 
in regards to change in health related quality of life. Methods: This prospective 
cost analysis of atopic dermatitis by reviewing the housekeeping account books 
of 32 patients was conducted and evaluated the economic impact of the disease 
by analyzing the completed questionnaires. To handle the potential uncertainties, 
we compared the results with the data released by the Health Insurance Review & 
Assessment Board on medical costs claimed by the health care facilities. Results: 
In regards to the cost of illness, direct cost of atopic dermatitis per patient during 
the 3 month study period was 541,280 KRW and expenditure on other atopic derma-
titis related products was 120,313 KRW. Extrapolated annual direct cost (including 
expenditures on other atopic dermatitis related product) per patient was 2,646,372 
KRW. Estimated annual indirect cost was 1,507,068 KRW. Annual cost of illness of 
atopic dermatitis, computed by adding up direct and indirect costs, was estimated 
to be 4,153,440 KRW. ConClusions: The annual total social cost on a national level 
was estimated at 5.8000 trillion KRW.
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objeCtives: There are three main funding sources of health system In Mongolia 
which are state budget, health insurance and out of pocket payment. Health insur-
ance funded health care service based on 115 DRG and total financing to health care 
organizations were 87.1 billion MNT in 2011. Health insurance rates 240000 MNT 
secondary and thirtary level of hospital by the same tariff. Aim of the study is to 
calculate 10 DRG costs which were spent 25 percent of the health insurance fund 
in 2012. Methods: We used both top down and bottom-up cost allocation method. 
Secondary data were used.  Results: Respiratory diseases finance is 9 percent 
higher than the real cost. Other 9 diagnostic groups finance were less than actual 
cost by 8-62%. That the total funding based on the number of cases nationwide, 
12,032,906,381 MNT funding was insufficient. ConClusions: Health insurance 
base tariff have to change based on the study while base rates should be different 
at secondary and thirtary level of health care organization.
PRS36
a PhaRmacoeconomic caRe analySiS of tuBeRculoSiS contRol in 
PakiStan
Iqbal M.S.1, Iqbal M.W.2, Bahari M.B.3, Khalid S.H.4, Iqbal M.Z.1
1Department of Clinical Pharmacy, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 
2Faculty of Law, Universiti Malaya,, Kualalumpur, Malaysia, 3Faculty of Law, Universiti Malaya, 
Kualalumpur, Malaysia, 4Department of Pharmaceutical Technology, School of Pharmaceutical 
Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia
objeCtives: To assess the direct and indirect medical costs incurred in 
the treatment of tuberculosis (TB) in patients attending public hospitals in 
Pakistan. Methods: A descriptive cross-sectional study was conducted in patients 
attending Accident and Emergency and TB wards of the hospitals in Pakistan by con-
venient-sampling technique. The direct and indirect medical costs were determined 
by various parameters like consultation fees, cost of medicines, travelling costs 
and laboratory test expenses etc. All obtained data were analyzed using descrip-
tive and inferential statistics. Results: The mean annual direct medical cost for 
a TB patient was around Rs. 17317.56 (US$ 176.26) and indirect medical cost was 
Rs. 12918.50 (US$ 131.48). It was also observed that ccomparatively higher direct 
and indirect medical costs per patient (p < 0.001) were associated with large and 
urban hospitals. Besides, association of indirect medical costs with gender and age 
were the persuasive predictors of the study. ConClusions: Severity of the disease, 
distance to the hospital and length of stay in the hospital were proportional to the 
direct and indirect medical costs. In Pakistan, a significant proportion of the direct 
medical cost for TB treatment is subsidized for the public.
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objeCtives: The cost of acute exacerbations of asthma had not been well stud-
ied in literature. The aim of this study was to identify and quantify the (average) 
cost of moderate and severe exacerbations of asthma in patients attending ter-
tiary-care setup in Malaysia. The related burden of exacerbations was also cal-
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over a 10-year horizon. A National Health Service (NHS) and personal social ser-
vices perspective was considered. The effectiveness of treatment was evaluated 
in terms of Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years 
(DALYs). Data were sourced from a phase II, placebo controlled trial of bedaquiline, 
NHS reference costs, and the literature. Costs and effectiveness were discounted 
at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis 
was conducted. Results: The total discounted cost per patient on B+BR was 
£107,123, compared with £116,616 for BR. The total discounted QALYs per patient 
were 4.85 for B+BR and 3.81 for BR. The addition of bedaquiline to BR resulted 
in cost-savings of £9,493 and an additional 1.04 QALYs pp over a 10-year period, 
and is therefore considered to be the dominant (less costly and more effective) 
strategy over BR. B+BR remained dominant versus BR in the majority of sensitivity 
analyses, with a 74% probability of being dominant versus BR in the probabilistic 
analysis. ConClusions: In the UK, bedaquiline is likely to be cost-effective and 
cost-saving, compared to the current standard of care for MDR-TB under a range 
of scenarios. Cost-savings over a 10 year period were realized from reductions in 
lengths of hospital stay, which offset bedaquiline drug costs. Bedaquiline remained 
cost-saving in several sensitivity analyses, highlighting the certainty surrounding 
the results of the model. These results also indicate that the B+BR regimen can 
provide significant social economic benefits versus the BR only regimen.
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objeCtives: To evaluate the long-term cost-effectiveness of umeclidinium bromide 
62.5 mcg OD (UMEC) compared to tiotropium bromide 18 mcg OD (TIO) for the 
maintenance treatment of COPD from the UK National Health Service perspec-
tive Methods: We utilized a recently developed, internally and externally validated 
linked equations COPD Cohort disease progression model. The treatment effect, 
expressed as change from baseline in forced expiratory volume in one second (FEV1) 
at 12 and 24 weeks estimated from a Bucher method indirect treatment comparison 
(ITC) analysis following a systematic review. UMEC price was set at parity price of 
£33.5/month to TIO. Model outcomes included exacerbations, life years, quality 
adjusted life years (QALYs) and costs/QALY. The time horizons investigated ranged 
from one to 20 years (lifetime) on a sliding one-year increment. Costs, survival, and 
QALYs after the first year were discounted at a rate of 3.5%. Health care costs were 
obtained from NHS reference costs (2011-12). Sensitivity analyses were performed 
to evaluate the robustness of the model to variations in the underlying input param-
eters and assumptions. Results: The ITC estimated change from baseline in trough 
FEV1 of 18.06mL (95%CI: -19.11, 55.23, p= 0.341) at 12 weeks and 3.97mL (95%CI: 
-38.30, 46.25, p= 0.854) at 24 weeks for UMEC compared with TIO. At price parity, 
UMEC dominated TIO with incremental QALY of 0.0009, incremental life years of 
0.0001 and cost reduction of £4.54. The sensitivity analyses suggested that variation 
in main parameters will not alter the behavior of the comparison between the two 
treatments. ConClusions: At price parity to TIO, UMEC may be considered as a 
cost-effective treatment alternative for maintenance bronchodilator treatment to 
relieve symptoms in patients with COPD in the UK.
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objeCtives: UMEC/VI is a long acting muscarinic agent (LAMA) and long acting beta 
agonist (LABA) combination therapy. This study evaluated the cost-effectiveness of 
UMEC/VI compared to tiotropium (18µg) from the UK National Health Service per-
spective. Methods: A linked equations cohort model developed using the patient 
level data from ECLIPSE study and validated using patient level data from TORCH 
study was used. The baseline patient characteristics were derived from UMEC/VI 
phase IIIa clinical programme and included symptomatic COPD patients. The treat-
ment effect expressed as change from baseline in forced expiratory volume in one 
second (FEV1) at 24 weeks was estimated using 3 tiotropium comparator phase 
IIIa trials and was assumed to last for at least 52 weeks following treatment initia-
tion. Model outcomes included exacerbations, life years, quality adjusted life years 
(QALYs) and costs/QALY. The timeframe for the analysis was patient lifetime and the 
discount rate for costs and outcomes was 3.5%. The price of UMEC/VI was varied to 
estimate the points at which it would be cost effective compared with the current 
standard of care tiotropium. Health care costs were obtained from NHS reference 
costs (2011-12). Results: The random effects meta-analysis estimated treatment 
benefit of 92.17ml (95% CI: 61.52, 122.82; p< 0.001) in FEV1for UMEC/VI compared with 
tiotropium. A lifetime model resulted in 0.009 fewer moderate-severe exacerbations 
per year on UMEC/VI. At parity price (£33.5/month), UMEC/VI dominated tiotro-
pium with a probability of 0.81 for being cost effective at £30,000/QALY threshold. 
The incremental cost effectiveness ratios were £11,080 and £22,178 at 5% and 10% 
price premium to tiotropium, respectively. ConClusions: At an appropriate price, 
UMEC/VI may be considered as a cost-effective treatment alternative for sympto-
matic patients with COPD.
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and severe exacerbations were also evaluated and the costs were set for one single 
event. Results: The total cost of mild COPD was € 26.22, moderate COPD € 30.26, 
severe COPD € 92.04 and for the very severe COPD € 267.64 for 1 patient/3 months. 
Expenses for bronchodilators also vary between different stages of COPD, for mild 
COPD it represented € 17.44, moderate COPD € 109.54, severe COPD € 219.58 and for 
very severe COPD € 206.15. Cost of treating exacerbations were set for one event - for 
moderate exacerbation € 67 and for severe exacerbation € 1060.27. ConClusions: 
In the management of COPD the most expensive are the costs of hospitalization, 
outpatient care and symptomatic treatment. The most costly is the management 
of the very severe COPD and severe exacerbation. This survey can be used as the 
source for cost inputs in pharmacoeconomic studies.
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objeCtives: The objective was to analyze the cost-effectiveness of a national immu-
nization program with pneumococcal conjugate vaccine (PCV): 10-valent pneumo-
coccal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) 
and 13-valent pneumococcal conjugate vaccine (PCV-13) in Romania. Methods: A 
published age stratified, deterministic, and static cohort model is used. This model 
highlights changes in cost and quality adjusted life years (QALYs) over time. Serotype 
specific disease incidence, age stratified disease incidence, mortality in the popu-
lation, vaccine costs and resource utilization costs were obtained from a General 
Practitioner reports database and epidemiological sources. The model compared 
identical immunization programs involving PHiD-CV and PCV-13 vaccines taking the 
payer perspective. A cohort of 201,104 Romanian infants was followed for four years. 
Same net indirect protection for invasive pneumococcal disease (IPD) was assumed 
for both vaccines. Results: With 80% vaccine uptake and 2+1 vaccination schedule, 
PHiD-CV dominated PCV-13 assuming price parity. Vaccination with PHiD-CV versus 
PCV-13 resulted in an offset for the health care budget of £22,948 (the main driver 
of this difference is the decrease in Acute Otitis Media (AOM) related costs – with a 
total of 4,663 cases prevented) and a total of 23 QALYs gained. Sensitivity analyses 
revealed robustness of the model results, confirmed the dominance of PHiD-CV 
over PCV-13 and substantiated model outcome driven by incremental efficacy of 
PHiD-CV in conjunction with high incidence AOM. ConClusions: According to the 
model, implementation of PHiD-CV vaccination program for infants in Romania will 
offer substantial benefits in terms of cost savings and improved health compared 
to an identical vaccination program involving PCV-13. PHiD-CV’s potential to better 
prevent AOM translates into incremental benefits and dominance of PHiD-CV over 
PCV-13 given that their impact on IPD is similar.
PRS42
coSt-effectiveneSS of a coPd diSeaSe management PRogRam in 
PRimaRy caRe: the Recode cluSteR Randomized tRial
Boland M.R.S.1, Kruis A.2, Tsiachristas A.1, Assendelft W.2, Gussekloo J.2, Blom C.3, Chavannes 
N.2, Rutten van-Molken M.1
1erasmus University Rotterdam, Rotterdam, The netherlands, 2Leiden University, Leiden, The 
netherlands, 3Stichting Zorgdraad Foundation, Oosterbeek, The netherlands
objeCtives: Disease management programs for chronic obstructive pulmonary 
disease (herein, COPD-DM) are currently implemented on a broad scale in the 
Netherlands. However, the evidence about their cost-effectiveness is still inconclusive. 
We aimed to conduct a cost-effectiveness analysis of a COPD-DM program in primary 
care in the Netherlands, called RECODE. In RECODE, a multidisciplinary primary care 
team was trained in motivational interviewing to improve life style, setting-up indi-
vidual care plans, early recognizing and managing of exacerbations, and implement-
ing clinical guidelines. In addition, clinical decision making was supported by audit 
and feedback reports provided by an ICT program and reimbursement of physical 
reactivation by a physiotherapist was provided. Methods: In a two-year cluster-ran-
domized controlled trial (1086 COPD patients, 40 clusters), the COPD-DM program was 
compared to usual care. As part of this trial we conducted a cost-effectiveness analysis 
to relate the effect of the COPD-DM on intermediate and final health outcomes to the 
costs from a health care and a societal perspective. Detailed self-reported health care 
utilization data were collected during the trial-period. Results: The 2-year inter-
vention costs of the training for professionals, the ICT, and the audit and feedback 
reports were estimated to be € 324 per patient. Excluding these costs, the intervention 
group had € 584 (95% CI € 86 to € 1,046) higher health care costs and € 645 (95% CI € 28 to 
€ 1,190) higher costs from the societal perspective compared to the usual care group. 
Health outcomes were similar in both groups, except for 0.04 (95% CI -0.07 to -0.01) 
less quality-adjusted life-years in the intervention group. ConClusions: RECODE 
was not cost-effective during the 2-year follow-up period. This is most likely due to 
the fact that the interventions targeted professionals instead of patients and were 
suboptimally implemented, the relatively mild COPD population, and the national 
reforms in COPD care that affected the usual care group.
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objeCtives: To evaluate the cost-effectiveness of adding bedaquiline to the inten-
sive phase of background regimens (BR) of drugs for multidrug-resistant tuberculosis 
(MDR-TB) in the United Kingdom (UK). Methods: A cohort-based Markov model 
was developed to estimate the incremental cost-effectiveness ratio of bedaqui-
line plus BR (B+BR) versus BR alone (BR) in the treatment of MDR-TB in the UK, 
